In May 2026, the pharmaceutical industry faced two major regulatory blows. On May 1, the Interpretation II on Several Issues Concerning the Application of Law in Handling Criminal Cases of Corruption and Bribery by the Supreme People's Court and the Supreme People's Procuratorate officially took effect. On May 7, the NMPA, together with the Ministry of Public Security, the National Health Commission, the National Healthcare Security Administration, and other departments, issued the Medical Representative Management Measures, which will officially take effect on August 1, 2026. These two policy sets connect one after another, forming a triple regulatory gate of criminal, administrative, and credit supervision, jointly announcing the end of the era of sales driven by kickbacks.
For pharmaceutical companies, behind every marketing action, compliance, professionalism, and transparency have become rigid requirements and may be checked by regulators at any time. Marketing models previously driven by personal relationships and gray-area methods are facing unprecedented compliance tests.
1. The Triple Regulatory Gates Close, Leaving No Gray Space for Pharma Marketing
The judicial interpretation effective May 1, 2026 lists food, drugs, and healthcare as key regulatory fields. The thresholds for crimes involving bribery of non-state personnel and offering bribes have been significantly lowered, and heavier punishment for bribery in healthcare is now certain. This means that practices where pharma companies delivered benefits to prescribing physicians through CSO accounting, academic activities, consulting services, and other conversion channels are now facing penetrating enforcement.
The Medical Representative Management Measures released on May 7 are even more targeted: the space for pharma companies to avoid compliance risk through third-party CSOs has been completely closed. Companies entrusting professional organizations must establish direct authorization relationships with every medical representative, and the marketing authorization holder bears joint liability for third-party actions. In other words, the practice of treating medical representative violations as personal employee issues and shifting responsibility away from the company has become history.
The new rules also define nine behavioral red lines for medical representatives, including conducting promotion without filing and registration, taking on drug sales tasks, counting physician prescription volumes, delivering benefits to medical personnel or their families, and illegally obtaining patient information. Medical institutions are also required to designate departments to receive medical representatives in a unified manner, and identities must be verified through the filing platform before promotion.
2. Compliance, Professionalism, Transparency: Three Keywords for Pharma Marketing
This regulatory transformation is pushing pharma marketing fully toward compliance, professionalism, and transparency.
Compliance is the bottom line. Regulatory checks will go beyond expense categories and examine transaction structures and benefit flows, requiring companies to prove that compliance systems operate effectively in practice, not merely exist in written policies. This means every step of pharma marketing activity, from activity initiation to representative execution, must withstand surprise inspections and checks at any time.
Professionalism is the way forward. The new rules require medical representatives to have a college degree or above and pass training assessments before taking up their positions. The industry is shifting from relationship-based to academic-based marketing. Pharma marketing teams must be able to serve physicians with evidence-based medical information, rather than drive prescriptions through personal relationships.
Transparency is the prerequisite. Regulators will impose joint disciplinary action through information sharing, clue transfer, and coordination between administrative enforcement and criminal justice. This places higher requirements on internal data management systems. Behind marketing actions, there must be clear and traceable data support, and all activity records should be searchable and verifiable.
3. Transformation Is Urgent, and Master Data Verification Becomes the Compliance Foundation
Facing the closing triple regulatory gates, pharmaceutical companies must act quickly. Compliance requires companies to establish complete marketing compliance management systems; professionalism requires true academic promotion capability; transparency requires all marketing activities to be accurately recorded and traced through data.
The prerequisite for all of this is the accuracy and completeness of master data. Core marketing actions such as academic promotion, expert management, and budget control are all built on HCP master data. If the data itself is inaccurate, with incomplete physician information, misplaced department affiliation, or expired qualification information, any compliance management built on that data loses reliability and may expose hard-to-explain gaps during regulatory checks.
In this context, pharmaceutical companies need professional master data verification services to solve traditional data management pain points: fragmented data sources, delayed updates, low manual efficiency, and hard-to-guarantee accuracy. Compliance, professionalism, and transparency begin with accurate data. Accurate data needs professional capability to protect it.
This is exactly the core value of MeDomino master data verification: using more accurate data and faster speed as the foundation to help pharma companies build a strong compliance base at the master data management level. From data collection and cleaning to continuous updates, MeDomino uses AI algorithms and years of industry experience to provide full-lifecycle master data management support, making the data behind marketing activities true, searchable, and able to withstand regulatory checks at any time.
4. MeDomino Master Data Verification: Accurate, Fast, and Full-Lifecycle Management
With years of data management experience in the life sciences industry and strong AI algorithm capabilities, MeDomino provides professional and efficient master data verification services for pharmaceutical companies. Centered on compliance, professionalism, and transparency, MeDomino helps companies build master data management capabilities from the source and respond effectively to normalized regulatory checks.
MeDomino's master data verification service has two core advantages:
First, accurate data - a ten-million-level HCP database and AI-driven precision verification
MeDomino has a database covering more than 4 million HCPs across China. Based on long-term industry experience and self-developed AI algorithms, we have built a complete master data verification system for pharmaceutical companies. Through automated data collection, cleaning, and cross-verification, MeDomino can effectively identify and correct information errors, conflicts, and omissions in master data, ensuring data unity and consistency.
At the compliance level, the data is legal and compliant, results are quantifiable, and business departments highly recognize the value, providing reliable foundational data protection for pharmaceutical companies facing regulatory checks.
Second, faster speed - automated verification and scaled processing
Traditional master data verification often relies on extensive manual work. From data collection and cleaning to review, a large-scale verification round can take months. Through an AI-driven automated verification system, MeDomino can complete precise processing of massive data in a shorter time and efficiently break collected data into usable and analyzable information.
This means that when pharmaceutical companies face regulatory checks, internal audits, or business changes, master data verification and updates no longer slow the organization down. Instead, they become a support system that responds quickly and provides timely feedback.
5. Full-Lifecycle Management: More Than One-Time Verification
Beyond the core advantages of accuracy and speed, MeDomino also provides full-lifecycle master data management services from data collection, cleaning, and verification to continuous updates:
- HCP360 all-around profiles: integrate multi-source data to build a complete expert profile database.
- Intelligent KOL identification: use big data and AI algorithms to quickly and accurately identify target experts.
- Intelligent tagging and segmentation: connect master data precisely with business scenarios and support diverse needs such as clinical research and academic promotion.
Final Thoughts
2026 is a critical year for the comprehensive upgrade of pharmaceutical compliance supervision. As major regulations such as the judicial interpretation and the Medical Representative Management Measures take effect, "behind every marketing action are compliance, professionalism, and transparency, and it may be checked by regulators at any time" will become the industry's new normal. Compliance, professionalism, and transparency begin with accurate data. Accurate data needs professional capability to protect it.
MeDomino master data verification is committed to helping pharmaceutical companies build a strong compliance foundation at the master data management level and respond calmly to normalized regulatory checks. From data verification to profile building, from AI algorithms to business enablement, what MeDomino is doing is making compliance evidence-based and marketing traceable to its source.
Let every academic investment withstand inspection, and let every promotional activity be transparent and traceable. This is both a regulatory requirement and the future MeDomino and the industry look forward to together.
